Blood-Based Biomarker for Parkinson’s Disease Market Size Worth USD 2,711.91 Million by 2034 | CAGR: 18.8%

The blood-based biomarker for Parkinson’s disease market size is expected to reach USD 2,711.91 million by 2034, according to a new study by Polaris Market Research. The report “Blood-Based Biomarker for Parkinson’s Disease Market Share, Size, Trends, Industry Analysis Report By Biomarker Type [Alpha-Synuclein (α-syn), Neurofilament Light Chain (Nfl)], By Application, By Technology Platform, By End User, By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Blood-based biomarkers for Parkinson’s disease are molecular indicators detectable in blood that provide insights into the presence, progression, and therapeutic response of the disease. These biomarkers are gaining prominence as healthcare systems focus on early-stage detection, aiming to shift from symptomatic treatment to timely intervention and prevention. The growing demand for minimally invasive diagnostic approaches is encouraging clinical researchers and diagnostic developers to advance blood-based assays capable of identifying Parkinson’s at its earliest stages. This trend is also being supported by rising awareness among clinicians regarding the utility of biomarkers in differentiating Parkinson’s from similar neurodegenerative disorders.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/blood-based-biomarker-parkinson-disease-market/request-for-sample

The blood-based biomarker for Parkinson’s disease market is shaped by the integration of multi-omics technologies to enhance biomarker discovery and validation. Advances in genomics, proteomics, and metabolomics are enabling a more comprehensive understanding of Parkinson’s disease at the molecular level, leading to the identification of novel blood-based biomarkers with improved specificity and sensitivity. This convergence of technology and clinical research is accelerating the pace of biomarker development and also expanding their applicability in clinical trials and personalized medicine. As a result, the market is evolving rapidly toward precision-driven, data-enabled diagnostic solutions.

Top of FormBlood-Based Biomarker for Parkinson’s Disease Market Report Highlights

• In terms of application, the diagnostic biomarkers segment led revenue generation with USD 204.10 million in 2024, due to their critical role in detecting Parkinson's during early/prodromal stages when intervention is most impactful.
• Based on biomarker type, the NfL biomarker segment is projected to register the highest CAGR of 19.00% during the forecast period, owing to its established utility as a sensitive neurodegeneration indicator across multiple neurological disorders.
• North America held a 45.00% global share in 2024, benefiting from its advanced healthcare systems and the concentrated presence of leading biomarker developers and research institutions.
• The market in Asia Pacific is expected to register a CAGR of 20.50% from 2025 to 2034, driven by investments in biomedical research, enhancements in diagnostic services, and rising awareness campaigns for diseases.           
• A few global key players in the blood-based biomarker for Parkinson’s disease market include Abbott Laboratories, Adx Neurosciences, Alamar Biosciences, betaSENSE, F. Hoffmann-La Roche Ltd, Merck KGaA, Proteome Sciences, QIAGEN N.V., Quanterix Corporation, and Thermo Fisher Scientific Inc.

Polaris Market Research has segmented the blood-based biomarker for Parkinson’s disease market report on the basis of biomarker type, application, technology platform, end user, and region:

By Biomarker Type Outlook (Revenue, USD Million, 2020–2034)

• Alpha-Synuclein (α-Syn)
• Neurofilament Light Chain (NfL)
• Inflammatory Markers
• Metabolic Biomarkers
• Others

By Application Outlook (Revenue, USD Million, 2020–2034)

• Diagnostic Biomarkers
• Prognostic Biomarkers
• Monitoring Biomarkers
• Therapeutic Response Biomarkers
• Others

By Technology Platform Outlook (Revenue, USD Million, 2020–2034)

• Alpha-Synuclein Seeding Amplification Assay (αSyn-SAA)
• ELISA-Based Assays
• Immunoassays
• Mass Spectrometry
• Others

By End User Outlook (Revenue, USD Million, 2020–2034)

• Hospitals and Clinics
• Diagnostic Laboratories
• Research Institutes
• Pharmaceutical Companies

By Regional Outlook (Revenue, USD Million, 2020–2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Vietnam
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa